Satellos Bioscience Inc. (MSLE) research

Satellos Bioscience Inc.

Sector: Healthcare
Industry: Biotechnology
Last price: $8.50
As of: 2026-10-02

Satellos Bioscience Inc. (MSLE): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-30.

As of 2026-09-30, the latest of: this ticker's 13F holdings load, its latest SEC filing date, and its latest signal other than 13F-derived signals. Source: SEC EDGAR filings for MSLE. Method and limitations.

COMPANY DOSSIER

See the full MSLE dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for MSLE on one page. Preview it with sample data, then open it live with a free account.

Preview the MSLE dossier

Active signals for MSLE

mediumEARNINGS_MISS2026-09-01
Q2-2026: Missed consensus by 20.9%, EPS $-0.56 vs $-0.4632 estimate
All 2026-09-01 signals →
mediumNEW_POSITION2026-08-16
CITADEL ADVISORS LLC new position in MSLE
All 2026-08-16 signals →
mediumNEW_POSITION2026-07-24
Point72 Asset Management, L.P. new position in MSLE
All 2026-07-24 signals →
mediumNEW_POSITION2026-07-24
MILLENNIUM MANAGEMENT LLC new position in MSLE
All 2026-07-24 signals →
mediumEARNINGS_MISS2026-06-29
Q4-2025: Missed consensus by 914.0% - EPS $-1.60008 vs $-0.1578 estimate
All 2026-06-29 signals →

FREE, NO ACCOUNT

Every signal on MSLE, as it fires

You are seeing 5 of 10 signals recorded on MSLE since 2026-06-10.

The five above landed across 4 days. The other 5 were recorded on 2 other days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in MSLE (2026Q2)

Manager / security	Market value	% portfolio	QoQ
Point72 Asset Management, L.P.CUSIP 80401L803 · 2026Q2	$5.3M	0.01%	,
MILLENNIUM MANAGEMENT LLCCUSIP 80401L803 · 2026Q2	$1.2M	0.00%	,
CITADEL ADVISORS LLCCUSIP 80401L803 · 2026Q2	$527K	0.00%	,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, MSLE

6-K2026-09-30
SEC EDGAR ↗
6-K2026-09-24
SEC EDGAR ↗
6-K2026-09-15
SEC EDGAR ↗
6-K2026-09-09
SEC EDGAR ↗
6-K2026-09-01
SEC EDGAR ↗
6-K2026-08-14
SEC EDGAR ↗
6-K2026-08-13
SEC EDGAR ↗
6-K2026-07-08
SEC EDGAR ↗
6-K2026-06-29
SEC EDGAR ↗
6-K2026-06-25
SEC EDGAR ↗

MSLE against its peers

MSLE's return on equity of -89.5% ranks in the 28th percentile of 22 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.

Metric	MSLE	Peer median	Percentile	n
Revenue FY	n/a	17.0M	n/a	15
Operating margin	n/a	-354.5%	n/a	14
Net margin	n/a	-171.5%	n/a	14
Return on equity	-89.5%	-49.2%	28	22

Peers (24): PEPG, CNTN, CHRS, PYXS, ORGO, NKTX, MDWD, DTIL, ORMP, ACOG, CMPX, IPHA, ADAG, NGEN, AVXL, ALXO, CUE, NAUT, ALEC, ELDN, XGN, NBP, NERV, TRDA. Left out: VRXA (no annual filing). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (MSLE: 40-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more MSLE signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to MSLEand get the insider, 13F, options, and confluence read in one view.